Open an account

Alvotech SA

ALVO · NASDAQ

$4.58−$0.21 (−4.38%)TodayMarket closed ·
Prev close $4.79

About ALVO

Alvotech is a biotechnology company, which engages in the development and manufacture of biosimilar medicines. The firm is focused on the development and manufacture of biosimilar medicines for patients globally. The company is engaged in developing a pipeline of monoclonal antibodies that target a variety of therapeutic areas including inflammatory diseases, oncology, and ophthalmology. The Company’s pipeline contains eight biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer. Its products pipeline includes AVT02, AVT04, AVT23, AVT03, AVT05, AVT06, AVT16, and AVT33. Its AVT02 is a monoclonal antibody and a biosimilar to Humira (adalimumab). AVT04 is a monoclonal antibody and a biosimilar candidate to Stelara (ustekinumab). The company has formed a network of strategic commercial partnerships to provide global reach and leverage expertise in markets that include the United States (U.S.), Europe, Japan, China, and other Asian countries and large parts of South America, Africa, and the Middle East.

Employees
1,460
Headquarters
Luxembourg
Listed
Nov 9, 2020
Sector
Health Care
Industry
Biotechnology
Website
alvotech.com

ALVO key statistics

Market cap
1.87B
Price-earnings ratio
0.00
Dividend yield
—
Average volume
1.07M
Volume
666.25K
Open price
$4.78
High today
$4.78
Low today
$4.57
52 Week high
$8.50
52 Week low
$2.94

Alvotech SA (ALVO) at a glance

As of Oct 23, 2026, Alvotech SA (ALVO) shares are priced at $4.58, giving the company a market cap of 1.87B and a price-to-earnings ratio of 0.00.

Today the stock has traded between $4.57 and $4.78. The current price is 0.3% above the day's low and 4.2% below its high.

Volume so far is 666.25K shares, below the average of 1.07M shares a day.

Over the past year Alvotech SA has ranged from $2.94 to $8.50, and now sits 29% of the way up that range.

Alvotech SA met or beat analyst EPS estimates in 4 of the last 8 quarters. In Q2 FY26 it reported -$0.11 per share against an estimate of -$0.0275.

The average analyst price target is $7.73, 68.9% above the current price, from 5 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

80%of 5 analyst ratings say Buy
  • Buy80.0%
  • Hold20.0%
  • Sell0.0%
Price target · 8 analystsAvg $7.73
Low
$4.04
Now
$4.58
High
$9.98

ALVO earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 4 of the last 8 quarters, by 268.3% on average.

  1. Q3 FY24: reported -$0.02 per share against an estimate of -$0.0571
  2. Q4 FY24: reported -$0.24 per share against an estimate of -$0.3932
  3. Q1 FY25: reported $0.35 per share against an estimate of -$0.1122
  4. Q2 FY25: reported $0.14 per share against an estimate of -$0.0306
  5. Q3 FY25: reported -$0.05 per share against an estimate of -$0.0204
  6. Q4 FY25: reported -$0.37 per share against an estimate of -$0.0459
  7. Q1 FY26: reported -$0.09 per share against an estimate of $0.017
  8. Q2 FY26: reported -$0.11 per share against an estimate of -$0.0275

ALVO news

  • 12 Health Care Stocks Moving In Monday's Intraday Session

  • Avi Kapoor

    Crude Oil Down 3%; XPeng Shares Fall After Q2 Results

  • Alvotech Q2 2026 Earnings Call Transcript

  • Press releaseGlobe Newswire

    Alvotech to present at upcoming investor conferences in June

  • Avi Kapoor

    Why nCino Shares Are Trading Higher By 18%; Here Are 20 Stocks Moving Premarket

  • Press releaseGlobe Newswire

    Alvotech to Report Fourth Quarter and Full Year 2025 Financial Results

  • Press releaseGlobe Newswire

    ALVO INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving Alvotech

  • Press releaseNewsfile

    ROSEN, LEADING INVESTOR COUNSEL, Encourages Alvotech Investors to Inquire About Securities Class Action Investigation - ALVO

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.